Bharat Parenterals Limited has issued a formal notice to its physical shareholders regarding a special window for re-lodgement of share transfer deeds, following regulatory compliance requirements under SEBI guidelines.

Regulatory Compliance Notice

The company published newspaper advertisements on April 08, 2026, in two prominent publications to ensure wide reach among shareholders. The notice appeared in the Ahmedabad Edition of "Business Standard" and the Vadodara Edition of "Vadodara Samachar", with the advertisement also made available on the company's website at www.bplindia.in .

SEBI Circular Implementation

The notice follows SEBI Circular No. HO/38/13/11(2)2026-MIRSD-POD/I/3750/2026 dated January 30, 2026, which established specific guidelines for physical share transfers. The regulatory framework addresses transfer deeds that were previously rejected due to document deficiencies or procedural issues.

Shareholder Guidelines

Eligible physical shareholders can re-lodge their share transfer deeds for processing within the specified timeframe. The company emphasized that only transfer deeds originally lodged before the April 01, 2019 deadline and subsequently rejected due to deficiencies will be considered for re-lodgement.

Transfer requests must be submitted along with requisite documents to the company's Registrar and Share Transfer Agent (R&TA) at Adroit Corporate Services Pvt. Ltd., located at 18-20, Jafferbhoy Industrial Estate, 1st Floor, Makwana Road, Marol Naka, Andheri East, Mumbai, Maharashtra-400059, or via email at info@adroitcorporate.com .

Processing Requirements

The company clarified that re-lodged shares for transfer will be processed exclusively in dematerialized form, following the due process prescribed by SEBI. Transfer deeds lodged after the April 01, 2019 deadline and rejected by the company will not be entertained under this special window provision.

The notice was signed by Sharmin Soni, Company Secretary and Compliance Officer (ICSI M. No: ACS-75694), ensuring proper authorization and regulatory compliance for the communication to shareholders.

Bharat parenterals Limited reported its Q3FY26 financial results for the quarter ended December 31, 2025, showing a mixed performance with revenue challenges offset by a strong order book position. The pharmaceutical company's standalone operations faced headwinds primarily due to timing-related delays in institutional segment execution.

Standalone Financial Performance

The company's standalone revenue from operations declined significantly on a year-on-year basis, reflecting timing mismatches in institutional purchase order releases.

Sequentially, revenue remained relatively stable at ₹41.41 crore compared to ₹41.70 crore in Q2FY26. The company's gross profit margin normalized to 39.4% in Q3FY26, compared to 44.1% in the previous quarter and 43.3% in Q3FY25.

Order Book Disclosure

For the first time, Bharat Parenterals disclosed its order book position to enhance investor visibility and predictability.

Management expects this order book to provide substantial support for FY27 performance, particularly in the first half of the fiscal year.

Consolidated Results

On a consolidated basis, the company's performance reflected ongoing investments in subsidiaries and regulated market platforms. The consolidated net loss increased to ₹44.00 million compared to ₹16.60 million in the previous year.

Subsidiary Performance Updates

Innoxel Lifesciences

Innoxel Lifesciences achieved a significant regulatory milestone during the quarter with the successful completion of its EU GMP inspection.

Management maintains revenue guidance of ₹60-65 crore for the full year and expects the subsidiary to move into profit after tax profitability in FY27.

Varenyam Healthcare

Varenyam Healthcare continued its growth trajectory in the domestic branded formulations segment, focusing on anaesthesia and related therapies.

Management Outlook

Management provided guidance for the immediate quarter and expressed confidence in the medium-term outlook despite current challenges.

Q4FY26 Expectations:

• Standalone revenue expected to improve to approximately ₹50-55 crore
• Sequential recovery over Q2 and Q3 base levels

FY26 Full Year:

• Company does not expect to achieve earlier full-year guidance
• Shortfall attributed to timing shifts in institutional execution

FY27 Outlook:

• Expected to benefit significantly from deferred order book execution
• Strong start anticipated in H1FY27

The company emphasized that current revenue softness represents timing delays rather than structural demand issues, with institutional execution typically being uneven quarter-to-quarter. The disclosed order book of ₹303 crore provides substantial visibility for future revenue recognition and execution.